STAAR Surgical Generates $464,000 in Cash from Operations During Thi...(se measures are a substitute for measure...),Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter
Date:11/2/2009
se measures are a substitute for measures determined in accordance with GAAP, and may not be comparable to the same measures as reported by other companies.
When reviewing financial information to assess the effectiveness of initiatives to enhance long-term performance by reducing expenses, management may eliminate the effect of significant non-recurring expenses in order to discern underlying trends. In the 2008 fiscal year, the Company's results were significantly affected by the following non-recurring expenses classified in the GAAP reconciliation table as "purchase A/C [accounting] charges": a $1.5 million purchase accounting charge related to inventory purchased in the acquisition of STAAR Japan, Inc. and a $3.8 million charge for the settlement of a pre-existing distribution arrangement in connection with the STAAR Japan, Inc. acquisition. Because the effect of purchase accounting charges can overwhelm the effect of meaningful trends in the Company's business performance, management evaluates its performance excluding these non-recurring items. The Company believes that this non-GAAP measure is also helpful to investors in discerning underlying trends. The table below shows the effects of the excluded non-recurring items.
The Company conducts a significant part of its activities outside the U.S. It receives sales revenue and pays expenses principally in U.S. dollars, Swiss francs, Japanese yen and Euros. The exchange rates between dollars and non-U.S. currencies can fluctuate greatly and can have a significant effect on our results when reported in U.S. dollars. When preparing its financial statements in conformance with GAAP, the Company translates foreign currency sales and expenses to dollars at the weighted average of exchange rates in effect during the period. As a result, the Company's reported performance may be significantly affected by currency fluctuations. In order to compare the Company's performance from period to
'/>"/>
| SOURCE STAAR Surgical Company Copyright©2009 PR Newswire. All rights reserved |
Related medicine technology :
1. STAAR Surgical to Present at the 20th Annual Oppenheimer Healthcare Conference in New York
2. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
3. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
5. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
6. New Non-Surgical Stem-Cell Procedure to Relieve Chronic Tendon Problems
7. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
8. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
9. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
10. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
11. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
Post Your Comments:
(Date:12/16/2009)... YORK, Dec. 16 Keryx Biopharmaceuticals, ... the initiation of a Phase 3 registration ... PI3K/Akt pathway inhibitor, in relapsed / refractory ... "A Phase 3 Randomized Study to Assess ... to the Combination of Bortezomib (Velcade®) and ...
(Date:12/16/2009)... -- , - ... a Total of Over,640 patients Ahead of ... NV (Euronext Brussels: THR), a biopharmaceutical company,focused ... treatments for eye,disease, vascular disease and cancer, ... of the second Phase III trial evaluating ...
(Date:12/15/2009)... Ga., Dec. 15 Immucor, Inc. (Nasdaq: ... systems to the blood transfusion industry, today announced that ... on Wednesday, January 6, 2010 after the market close. ... January 7, 2010 at 8:30 a.m. (Eastern Time) to ... to participate in this conference call by dialing 1-888-324-9321 ...
Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 2Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 3Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 4Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 5Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 6Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 7ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar 63092 1Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar 63092 2Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar 63092 3Traceability Institute Comments on Improving Food Safety System for Consumers at Food and Drug Administration 28FDA 29 and Food Safety and Inspection 63090 1Traceability Institute Comments on Improving Food Safety System for Consumers at Food and Drug Administration 28FDA 29 and Food Safety and Inspection 63090 2Human Rights Denied 3A Obama Leaves 75 Million Children Behind 63088 1Human Rights Denied 3A Obama Leaves 75 Million Children Behind 63088 2[0] Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma[0] ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease[0] Immucor to Announce Fiscal Second Quarter Financial Results on Wednesday, January 6, 2010
... 2007 /PRNewswire-FirstCall/ --,Phosphagenics Limited (AIM: PSG) announced ... Phase 1b clinical trial to demonstrate the,efficacy ... its transdermal,insulin product, TPM-02/Insulin, containing long-acting insulin.,The ... second quarter of,2007. , TPM-02/Insulin gel is ...
... ON, May 02, 2007 /PRNewswire-FirstCall/ - ... that identifies, develops,and commercializes differentiated products ... from its randomized,placebo-controlled Phase IIb trial ... post-operative pain following orthopedic surgery.,AeroLEF(TM) met ...
Other Medicine Technology:Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical,Trial in Second Quarter 2YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain 2YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain 3(Date:12/16/2009)... Market Expansion , ... Ramat-Gan, Israel (PRWEB) December 16, ... Web sites and companies, today announced a record year of growth ... its launch on July 2008, Kampyle has processed more than 12 ... than 30,000 customers in 191 countries., , ,Kampyle pioneered the ...
(Date:12/16/2009)... SCHAFFHAUSEN, Switzerland, Dec. 16 Tyco International ... the nomination of Michael E. Daniels for election ... company,s Annual General Meeting on March 10, 2010. ... of the Global Technology Services group of International ... worldwide responsibility for IBM,s Global Services business operations ...
(Date:12/16/2009)... Medizone International, Inc. (OTC Bulletin Board: ... Directors and the Board of Medizone New Zealand ... Inc. holds a 50% interest, agreed on December ... reconvey to Medizone International all global marketing rights ... Chairman, Edwin G. Marshall said, "Time has eroded ...
(Date:12/16/2009)... the ,70s, study finds , , TUESDAY, Dec. 15 (HealthDay ... United States than it was more than 30 years ... compared National Health and Nutrition Examination Survey data from ... and from 8,339 black and white participants from 1999 ... old. , The prevalence of myopia increased from 25 ...
(Date:12/16/2009)... in triathalons and appeared on The Amazing Race ... to think of herself as part human, part machine. , ... 34-year-old triathlete likes to describe herself. When she,s not training ... school auditoriums or posing nude with her metal leg crossed ... latest ESPN Body Issue. , She is the ...
Breaking Medicine News(10 mins):Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 2Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 3Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 4Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 5Health News:Tyco International Files Preliminary Proxy Proposing Election of New Director 2Health News:Medizone International, Inc. Approves Repurchase of Global Marketing Rights 2Health News:Amputee Athlete Tells Her Story 2Health News:Amputee Athlete Tells Her Story 3Health News:Amputee Athlete Tells Her Story 4[0] Kampyle Experiences Record Growth in 2009 with 25,000 New Customers [0] Tyco International Files Preliminary Proxy Proposing Election of New Director[0] Medizone International, Inc. Approves Repurchase of Global Marketing Rights[0] Nearsightedness on the Increase[0] Amputee Athlete Tells Her Story
... new form of tuberculosis should be isolated and confined ... a "potentially explosive international health crisis," according to a ... harsh measures are justified given the "extreme risk" posed ... in South Africa, they argue in today's edition of ...
... offers hope for treating those with nicotine addiction, scientists have come ... the brain called the insula can result in a person not ... center of the brain and is thought to translate information from ... or cravings for a drug. , The study published ...
... virus causing Rift Valley Fever has outmanoeuvred local and ... and Coast provinces to land// in Maragua, Central province, ... the killer bug could be headed for Nairobi. ... Livestock Development, with help from World Health Organisation (WHO) ...
... major role in deadly prion diseases by smashing up clusters ... brain illnesses to quickly spread, new Brown University research shows. ... they might reveal a way to control the spread of ... that inhibits this fragmentation process, it could substantially slow the ...
... of a mathematical model, suggest that international //cooperation to ... deal with an emerging pandemic. ,‘Bird flu’ ... epidemic yet because it rarely passes between people. If ... months to develop a vaccine effective against the new ...
... findings that lend support to the double dose vaccination of ... , Publishing results in the Journal of Pediatrics, Dr ... City, and colleagues said their findings confirmed the effectiveness of ... between 6 and 21 months. , The researchers ...
Other Medicine News:Health News:Quarantine Sought For Harsh TB Strain 2Health News:Chain-Smokers can Kick the Habit –A ‘brainy’ I 2Health News:Kenya: Alert As Virus Leaps Over Buffer Zone 2Health News:Kenya: Alert As Virus Leaps Over Buffer Zone 3Health News:Single Protein Plays A Major Role In Prion Diseases 2... innovative & portable FireFly LED light offers ... With the new FireFly LED you'll get ... go whereever your practice demands. High center-beam ... on your procedures, while the rechargeable battery ...
Easy pull-on design for continuous chin compression and support feature our exclusive Non-Slip Dome™...
For face-lifts and submental liposuction...
Very compressive support for submental liposuction...
Medicine Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |